ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells

Autophagy

Volumn 12, Issue 6, 2016, Pages 936-948

  Karvela, Maria ^a   Baquero, Pablo ^b   Kuntz, Elodie M ^c   Mukhopadhyay, Arunima ^a   Mitchell, Rebecca ^b   Allan, Elaine K ^d   Chan, Edmond ^e   Kranc, Kamil R ^f   Calabretta, Bruno ^g   Salomoni, Paolo ^h   Gottlieb, Eyal ^c   Holyoake, Tessa L ^a   Helgason, G Vignir ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^e UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ATG7; autophagy; chronic myeloid leukemia; energy metabolism; erythroid differentiation; glycolysis; oxidative phosphorylation; reactive oxygen species; tyrosine kinase inhibitor

Indexed keywords

CARBON; CD34 ANTIGEN; GLUCOSE; PROTEIN; PROTEIN ATG7; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; AUTOPHAGY RELATED PROTEIN 7; PROTEIN KINASE INHIBITOR;

AEROBIC METABOLISM; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL DEATH; CELL DIFFERENTIATION; CELL METABOLISM; CELL SURVIVAL; CITRIC ACID CYCLE; CONTROLLED STUDY; ENERGY METABOLISM; ERYTHROID CELL; GENE SILENCING; GLYCOLYSIS; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MITOCHONDRIAL RESPIRATION; OXIDATIVE PHOSPHORYLATION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROTEIN EXPRESSION; STEM CELL; ANIMAL; CELL RESPIRATION; CHRONIC MYELOID LEUKEMIA; DISEASE MODEL; DRUG EFFECTS; GENE DELETION; HEMATOPOIETIC STEM CELL; K-562 CELL LINE; METABOLIC FLUX ANALYSIS; METABOLISM; METABOLOME; MITOCHONDRION; MOUSE; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME;

ANIMALS; ANTIGENS, CD34; AUTOPHAGY; AUTOPHAGY-RELATED PROTEIN 7; CELL DIFFERENTIATION; CELL RESPIRATION; CELL SURVIVAL; CITRIC ACID CYCLE; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; GENE DELETION; GENE KNOCKDOWN TECHNIQUES; GLYCOLYSIS; HEMATOPOIETIC STEM CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLIC FLUX ANALYSIS; METABOLOME; MICE; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; PHILADELPHIA CHROMOSOME; PROTEIN KINASE INHIBITORS; REACTIVE OXYGEN SPECIES; STEM CELLS;

EID: 84966714967     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.1080/15548627.2016.1162359     Document Type: Article

References (59)

1. J.D.Rowley. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290-3; PMID:4126434; http://dx.doi.org/10.1038/243290a0
2. J.B.Konopka, S.M.Watanabe, O.N.Witte. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37:1035-42; PMID:6204766; http://dx.doi.org/10.1016/0092-8674(84)90438-0
3. J.Groffen, J.R.Stephenson, N.Heisterkamp, A.de Klein, C.R.Bartram, G.Grosveld. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36:93-9; PMID:6319012; http://dx.doi.org/10.1016/0092-8674(84)90077-1
4. T.L.Holyoake, G.V.Helgason. Do we need more drugs for chronic myeloid leukemia? Immunol Rev 2015; 263:106-23; PMID:25510274; http://dx.doi.org/10.1111/imr.12234
5. S.G.O'Brien, F.Guilhot, R.A.Larson, I.Gathmann, M.Baccarani, F.Cervantes, J.J.Cornelissen, T.Fischer, A.Hochhaus, T.Hughes, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004; PMID:12637609; http://dx.doi.org/10.1056/NEJMoa022457
6. F.X.Mahon, D.Rea, J.Guilhot, F.Guilhot, F.Huguet, F.Nicolini, L.Legros, A.Charbonnier, A.Guerci, B.Varet, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11:1029-35; PMID:20965785; http://dx.doi.org/10.1016/S1470-2045(10)70233-3
7. M.E.Gorre, M.Mohammed, K.Ellwood, N.Hsu, R.Paquette, P.N.Rao, C.L.Sawyers. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-80; PMID:11423618; http://dx.doi.org/10.1126/science.1062538
8. R.Bhatia, M.Holtz, N.Niu, R.Gray, D.S.Snyder, C.L.Sawyers, D.A.Arber, M.L.Slovak, S.J.Forman. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101:4701-7; PMID:12576334; http://dx.doi.org/10.1182/blood-2002-09-2780
9. A.S.Corbin, A.Agarwal, M.Loriaux, J.Cortes, M.W.Deininger, B.J.Druker. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121:396-409; PMID:21157039; http://dx.doi.org/10.1172/JCI35721
10. A.Hamilton, G.V.Helgason, M.Schemionek, B.Zhang, S.Myssina, E.K.Allan, F.E.Nicolini, C.Muller-Tidow, R.Bhatia, V.G.Brunton, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012; 119:1501-10; PMID:22184410; http://dx.doi.org/10.1182/blood-2010-12-326843
11. T.Skorski, P.Kanakaraj, M.Nieborowska-Skorska, M.Z.Ratajczak, S.C.Wen, G.Zon, A.M.Gewirtz, B.Perussia, B.Calabretta. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86:726-36; PMID:7606002
12. O.H.Yilmaz, R.Valdez, B.K.Theisen, W.Guo, D.O.Ferguson, H.Wu, S.J.Morrison. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441:475-82; PMID:16598206; http://dx.doi.org/10.1038/nature04703
13. J.Zhang, J.C.Grindley, T.Yin, S.Jayasinghe, X.C.He, J.T.Ross, J.S.Haug, D.Rupp, K.S.Porter-Westpfahl, L.M.Wiedemann, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006; 441:518-22; PMID:16633340; http://dx.doi.org/10.1038/nature04747
14. B.Gan, E.Sahin, S.Jiang, A.Sanchez-Aguilera, K.L.Scott, L.Chin, D.A.Williams, D.J.Kwiatkowski, R.A.DePinho. mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci U S A 2008; 105:19384-9; PMID:19052232; http://dx.doi.org/10.1073/pnas.0810584105
15. L.Galluzzi, F.Pietrocola, B.Levine, G.Kroemer. Metabolic control of autophagy. Cell 2014; 159:1263-76; PMID:25480292; http://dx.doi.org/10.1016/j.cell.2014.11.006
16. R.Mathew, S.Kongara, B.Beaudoin, C.M.Karp, K.Bray, K.Degenhardt, G.Chen, S.Jin, E.White. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 2007; 21:1367-81; PMID:17510285; http://dx.doi.org/10.1101/gad.1545107
17. B.Levine, D.J.Klionsky. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004; 6:463-77; PMID:15068787; http://dx.doi.org/10.1016/S1534-5807(04)00099-1
18. E.Sandilands, B.Serrels, D.G.McEwan, J.P.Morton, J.P.Macagno, K.McLeod, C.Stevens, V.G.Brunton, W.Y.Langdon, M.Vidal, et al. Autophagic targeting of Src promotes cancer cell survival following reduced FAK signalling. Nat Cell Biol 2012; 14:51-60; http://dx.doi.org/10.1038/ncb2386
19. D.J.Goussetis, E.Gounaris, E.J.Wu, E.Vakana, B.Sharma, M.Bogyo, J.K.Altman, L.C.Platanias. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood 2012; 120:3555-62; PMID:22898604; http://dx.doi.org/10.1182/blood-2012-01-402578
20. I.Kim, S.Rodriguez-Enriquez, J.J.Lemasters. Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys 2007; 462:245-53; PMID:17475204; http://dx.doi.org/10.1016/j.abb.2007.03.034
21. C.Bellodi, M.R.Lidonnici, A.Hamilton, G.V.Helgason, A.R.Soliera, M.Ronchetti, S.Galavotti, K.W.Young, T.Selmi, R.Yacobi, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119:1109-23; PMID:19363292; http://dx.doi.org/10.1172/JCI35660
22. G.V.Helgason, M.Karvela, T.L.Holyoake. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 2011; 118:2035-43; PMID:21693757; http://dx.doi.org/10.1182/blood-2011-01-330621
23. J.D.Rabinowitz, E.White. Autophagy and metabolism. Science 2010; 330:1344-8; PMID:21127245; http://dx.doi.org/10.1126/science.1193497
24. N.Zamboni, S.M.Fendt, M.Ruhl, U.Sauer. (13)C-based metabolic flux analysis. Nat Protoc 2009; 4:878-92; PMID:19478804; http://dx.doi.org/10.1038/nprot.2009.58
25. J.M.Buescher, M.R.Antoniewicz, L.G.Boros, S.C.Burgess, H.Brunengraber, C.B.Clish, R.J.DeBerardinis, O.Feron, C.Frezza, B.Ghesquiere, et al. A roadmap for interpreting C metabolite labeling patterns from cells. Curr Opin Biotechnol 2015; 34:189-201; PMID:25731751; http://dx.doi.org/10.1016/j.copbio.2015.02.003
26. I.Tanida, N.Mizushima, M.Kiyooka, M.Ohsumi, T.Ueno, Y.Ohsumi, E.Kominami. Apg7p/Cvt2p: A novel protein-activating enzyme essential for autophagy. Mol Biol Cell 1999; 10:1367-79; PMID:10233150; http://dx.doi.org/10.1091/mbc.10.5.1367
27. I.Tanida, E.Tanida-Miyake, T.Ueno, E.Kominami. The human homolog of Saccharomyces cerevisiae Apg7p is a Protein-activating enzyme for multiple substrates including human Apg12p, GATE-16, GABARAP, and MAP-LC3. J Biol Chem 2001; 276:1701-6; PMID:11096062; http://dx.doi.org/10.1074/jbc.C000752200
28. R.Lock, S.Roy, C.M.Kenific, J.S.Su, E.Salas, S.M.Ronen, J.Debnath. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell 2011; 22:165-78; PMID:21119005; http://dx.doi.org/10.1091/mbc.E10-06-0500
29. G.Bjorkoy, T.Lamark, A.Brech, H.Outzen, M.Perander, A.Overvatn, H.Stenmark, T.Johansen. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005; 171:603-14; PMID:16286508; http://dx.doi.org/10.1083/jcb.200507002
30. D.J.Klionsky, F.C.Abdalla, H.Abeliovich, R.T.Abraham, A.Acevedo-Arozena, K.Adeli, L.Agholme, M.Agnello, P.Agostinis, J.A.Aguirre-Ghiso, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8:445-544; PMID:22966490; http://dx.doi.org/10.4161/auto.19496
31. M.Mortensen, E.J.Soilleux, G.Djordjevic, R.Tripp, M.Lutteropp, E.Sadighi-Akha, A.J.Stranks, J.Glanville, S.Knight, S.E.Jacobsen, et al. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med 2011; 208:455-67; PMID:21339326; http://dx.doi.org/10.1084/jem.20101145
32. F.Liu, J.Y.Lee, H.Wei, O.Tanabe, J.D.Engel, S.J.Morrison, J.L.Guan. FIP200 is required for the cell-autonomous maintenance of fetal hematopoietic stem cells. Blood 2010; 116:4806-14; PMID:20716775; http://dx.doi.org/10.1182/blood-2010-06-288589
33. M.Mortensen, D.J.Ferguson, M.Edelmann, B.Kessler, K.J.Morten, M.Komatsu, A.K.Simon. Loss of autophagy in erythroid cells leads to defective removal of mitochondria and severe anemia in vivo. Proc Natl Acad Sci U S A 2010; 107:832-7; PMID:20080761; http://dx.doi.org/10.1073/pnas.0913170107
34. M.V.Stankov, M.El Khatib, B.Kumar Thakur, K.Heitmann, D.Panayotova-Dimitrova, J.Schoening, J.P.Bourquin, N.Schweitzer, M.Leverkus, K.Welte, et al. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia 2014; 28:577-88; PMID:24080946; http://dx.doi.org/10.1038/leu.2013.264
35. B.H.Robinson, R.Petrova-Benedict, J.R.Buncic, D.C.Wallace. Nonviability of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts. Biochem Med Metab Biol 1992; 48:122-6; PMID:1329873; http://dx.doi.org/10.1016/0885-4505(92)90056-5
36. L.D.Marroquin, J.Hynes, J.A.Dykens, J.D.Jamieson, Y.Will. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 2007; 97:539-47; PMID:17361016; http://dx.doi.org/10.1093/toxsci/kfm052
37. W.B.Novoa, A.D.Winer, A.J.Glaid, G.W.Schwert. Lactic dehydrogenase. V. Inhibition by oxamate and by oxalate. J Biol Chem 1959; 234:1143-8; PMID:13654335
38. E.Owusu-Ansah, U.Banerjee. Reactive oxygen species prime Drosophila haematopoietic progenitors for differentiation. Nature 2009; 461:537-41; PMID:19727075; http://dx.doi.org/10.1038/nature08313
39. Z.Tothova, R.Kollipara, B.J.Huntly, B.H.Lee, D.H.Castrillon, D.E.Cullen, E.P.McDowell, S.Lazo-Kallanian, I.R.Williams, C.Sears, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007; 128:325-39; PMID:17254970; http://dx.doi.org/10.1016/j.cell.2007.01.003
40. B.B.Lozzio, C.B.Lozzio, E.G.Bamberger, A.S.Feliu. A multipotential leukemia cell line (K-562) of human origin. Proc Soc Exp Biol Med 1981; 166:546-50; PMID:7194480; http://dx.doi.org/10.3181/00379727-166-41106
41. X.H.Liang, S.Jackson, M.Seaman, K.Brown, B.Kempkes, H.Hibshoosh, B.Levine. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999; 402:672-6; PMID:10604474; http://dx.doi.org/10.1038/45257
42. K.R.Kranc, H.Schepers, N.P.Rodrigues, S.Bamforth, E.Villadsen, H.Ferry, T.Bouriez-Jones, M.Sigvardsson, S.Bhattacharya, S.E.Jacobsen, et al. Cited2 is an essential regulator of adult hematopoietic stem cells. Cell Stem Cell 2009; 5:659-65; PMID:19951693; http://dx.doi.org/10.1016/j.stem.2009.11.001
43. B.M.Elzinga, M.J.Nyhan, L.C.Crowley, T.R.O'Donovan, M.R.Cahill, S.L.McKenna. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein. Am J Hematol 2013; 88:455-62; PMID:23440701; http://dx.doi.org/10.1002/ajh.23428
44. T.Finkel, N.J.Holbrook. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408:239-47; PMID:11089981; http://dx.doi.org/10.1038/35041687
45. X.Mao, C.R.Yu, W.H.Li, W.X.Li. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res 2008; 18:879-88; PMID:18663379; http://dx.doi.org/10.1038/cr.2008.86
46. M.A.Essers, S.Weijzen, A.M.de Vries-Smits, I.Saarloos, N.D.de Ruiter, J.L.Bos, B.M.Burgering. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 2004; 23:4802-12; PMID:15538382; http://dx.doi.org/10.1038/sj.emboj.7600476
47. T.R.Kwon, S.J.Jeong, H.J.Lee, H.J.Lee, E.J.Sohn, J.H.Jung, J.H.Kim, D.B.Jung, J.Lu, S.H.Kim. Reactive oxygen species-mediated activation of JNK and down-regulation of DAXX are critically involved in penta-O-galloyl-β-d-glucose-induced apoptosis in chronic myeloid leukemia K562 cells. Biochem Biophys Res Commun 2012; 424:530-7; PMID:22771329; http://dx.doi.org/10.1016/j.bbrc.2012.06.150
48. S.J.Stein, A.S.Baldwin. NF-kappaB suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death. Oncogene 2011; 30:4557-66; PMID:21625221; http://dx.doi.org/10.1038/onc.2011.156
49. N.Biswas, S.K.Mahato, A.A.Chowdhury, J.Chaudhuri, A.Manna, J.Vinayagam, S.Chatterjee, P.Jaisankar, U.Chaudhuri, S.Bandyopadhyay. ICB3E induces iNOS expression by ROS-dependent JNK and ERK activation for apoptosis of leukemic cells. Apoptosis 2012; 17:612-26; PMID:22252531; http://dx.doi.org/10.1007/s10495-011-0695-9
50. P.Isakson, M.Bjoras, S.O.Boe, A.Simonsen. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood 2010; 116:2324-31; PMID:20574048; http://dx.doi.org/10.1182/blood-2010-01-261040
51. M.Humbert, C.Mueller, M.F.Fey, M.P.Tschan. Inhibition of damage-regulated autophagy modulator-1 (DRAM-1) impairs neutrophil differentiation of NB4 APL cells. Leuk Res 2012; 36:1552-6; PMID:22981223; http://dx.doi.org/10.1016/j.leukres.2012.08.024
52. D.Brigger, B.E.Torbett, J.Chen, M.F.Fey, M.P.Tschan. Inhibition of GATE-16 attenuates ATRA-induced neutrophil differentiation of APL cells and interferes with autophagosome formation. Biochem Biophys Res Commun 2013; 438:283-8; PMID:23891751; http://dx.doi.org/10.1016/j.bbrc.2013.07.056
53. N.Orfali, T.R.O'Donovan, M.J.Nyhan, A.Britschgi, M.P.Tschan, M.R.Cahill, N.P.Mongan, L.J.Gudas, S.L.McKenna. Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation. Exp Hematol 2015; 43(9):781-93.e2; PMID:25986473
54. P.Maycotte, S.Aryal, C.T.Cummings, J.Thorburn, M.J.Morgan, A.Thorburn. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 2012; 8:200-12; PMID:22252008; http://dx.doi.org/10.4161/auto.8.2.18554
55. W.Zhang, K.B.Hamman, J.Spelman, P.LeRoy, J.Lee, C.Tsu, J.M.Gavin, H.Liao, H.Loke, N.Bump, et al. Identification of small molecule inhibitors of ATG7. Keystone Symposia; Autophagy 2011:Abstract 367, pg. 122.
56. W.E.Dowdle, B.Nyfeler, J.Nagel, R.A.Elling, S.Liu, E.Triantafellow, S.Menon, Z.Wang, A.Honda, G.Pardee, et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol 2014; 16(11):1069-79; PMID:25327288
57. K.J.Petherick, O.J.Conway, C.Mpamhanga, S.A.Osborne, A.Kamal, B.Saxty, I.G.Ganley. Pharmacological Inhibition of ULK1 Blocks mTOR-Dependent Autophagy. J Biol Chem 2015; 290:11376-83.
58. R.Bago, N.Malik, M.J.Munson, A.R.Prescott, P.Davies, E.Sommer, N.Shpiro, R.Ward, D.Cross, I.G.Ganley, et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. Biochem J 2014; 463:413-27; PMID:25177796; http://dx.doi.org/10.1042/BJ20140889
59. K.Rothe, H.Lin, K.B.Lin, A.Leung, H.M.Wang, M.Malekesmaeili, R.R.Brinkman, D.L.Forrest, S.M.Gorski, X.Jiang. The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells. Blood 2014; 123:3622-34; PMID:24755409; http://dx.doi.org/10.1182/blood-2013-07-516807